Allogeneic hematopoietic stem cell transplantation in children with sickle cell disease

Research output: Contribution to journalArticlepeer-review

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents the only curative treatment for sickle cell disease (SCD), being successful in around 85-90% of patients. Mortality and long-term morbidity (including infertility, gonadal failure, and chronic graft-vs.-host disease) associated with conventional approaches curtail the number of patients who undergo allo-HSCT. Recently, it has been demonstrated that cord blood is as effective as and possibly safer than bone marrow in pediatric patients with SCD. Likewise, transplant strategies based on the use of reduced-intensity regimens and the induction of mixed chimerism have been explored to decrease allo-HSCT short- and long-term complications.

Original languageEnglish
Pages (from-to)372-376
Number of pages5
JournalPediatric Blood and Cancer
Volume59
Issue number2
DOIs
Publication statusPublished - Aug 2012

Keywords

  • Allogeneic hematopoietic stem cell transplantation
  • Cord blood transplantation
  • Mixed chimerism
  • Sickle cell disease

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Fingerprint Dive into the research topics of 'Allogeneic hematopoietic stem cell transplantation in children with sickle cell disease'. Together they form a unique fingerprint.

Cite this